Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.
Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences.
To overcome a crowded patent market, a potential solution is to seek a declaration of obviousness, which has a basis in UK law stemming from Arrow Generics v Merck. Richard Roberts of Potter Clarkson reports.
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.
The UK’s vote to leave the EU may allow Britain to replace the SPC regulation—an often-criticised piece of law—and take a fresh approach to the system governing these rights, say Paul England and Matthew Royle of Taylor Wessing.
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.
The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.
The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.